Panel Discussion Is 2024 the Year of Dry AMD?: Evaluating Current Safety, Delivery & Regulatory Challenges, Recent Successes with Approved GA Drugs & the Future of Dry AMD & GA Drug Development
Time: 9:00 am
day: Conference Day 1
Details:
- Discussing the potential of targeting multiple pathways, such as complement and inflammasomes, with a single drug to halt disease progression
- Exploring the potential of combination therapies to tackle multifaceted challenges and revolutionize treatment paradigms for early, intermediate and late AMD
- Uncovering novel preclinical models that can recapitulate the macular microenvironment in dry AMD and GA
- Reviewing the different drug delivery techniques such as intravitreal and suprachoroidal injections as potential methods to reduce injection frequence and improve patient compliance
